Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. | Zendy

Jan H. Schornagel | Zendy; Jaap Verweij | Zendy; P H de Mulder | Zendy; F. Cognetti | Zendy; Jan B. Vermorken | Zendy; P Cappelaere | Zendy; P. Armand | Zendy; J. Wildiers | Zendy; Alexander de Graeff | Zendy; M. Clavel | Zendy

Open Access

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.

Author(s) -

Jan H. Schornagel,

Jaap Verweij,

P H de Mulder,

F. Cognetti,

Jan B. Vermorken,

P Cappelaere,

P. Armand,

J. Wildiers,

Alexander de Graeff,

M. Clavel

Publication year - 1995

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.1995.13.7.1649

Subject(s) - medicine , toxicity , antifolate , methotrexate , gastroenterology , surgery , chemotherapy , epidermoid carcinoma , radiation therapy , phases of clinical research , stomatitis , head and neck cancer , randomized controlled trial , cancer , antimetabolite

To compared the response rates and the toxicity of the new antifolate edatrexate (EDX) with that of methotrexate (MTX) in a randomized trial in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCC) and to compare the durations of response and survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research